Oncology Medical News about high risk of developing breast cancer;sertraline;controlling hot flashes

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

The efficacy of sertraline for controlling hot flashes in women with or at high risk of developing breast cancer
Breast Cancer Research and Treatment, 06/09/09

Wu MF et al. - In a trial to evaluate the efficacy of sertraline for controlling hot flashes in women with or at high risk of breast cancer, it appears that the study failed to demonstrate effectiveness of sertraline in attenuating hot flashes in women with or at high risk of developing breast cancer who were not recommended to take hormone replacement therapy.

Methods

All participants were asked to complete hot flash diaries.
Participants reporting wkly hot flash scores >15 during baseline wk underwent a 1-wk single-blind placebo run-in.
Those reporting hot flash score reductions >50% following placebo run-in were excluded.
The remaining women received an assigned treatment for 4 wks.

Results

Both groups’ demographic and clinical characteristics were similar with a greater decline, but not statistically significant, in hot flash frequencies and scores in the sertraline-treated group vs the placebo.
Emotional well-being improved significantly in the sertraline group.

<< Previous
nab-paclitaxel weekly or every 3 weeks compared to standard...

Next >>
The relationship between surgical factors and margin status after...